deltatrials

Her2/neu negative Trials in St. Louis, United States

Conditions / Her2/neu negative / St. Louis, United States

Her2/neu negative has been the subject of sustained clinical investigation across multiple research sites.

10 total trials for this combination

Trials

NCT ID Title Status Phase
NCT02115282 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic ACTIVE_NOT_RECRUITING
NCT02115282 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic ACTIVE_NOT_RECRUITING
NCT03633331 Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer COMPLETED
NCT02115282 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic ACTIVE_NOT_RECRUITING
NCT03633331 Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer COMPLETED
NCT03633331 Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer COMPLETED
NCT02488967 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer ACTIVE_NOT_RECRUITING PHASE3
NCT03633331 Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer COMPLETED
NCT03633331 Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer COMPLETED
NCT02115282 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic ACTIVE_NOT_RECRUITING

Related Pages